City of Hope | Strategic Alliance Partners

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

Pule Wang, MD, discusses CNS bridging radiotherapy prior to CAR T-cell therapy in B-cell lymphomas.

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

Alexis LeVee, MD, discusses T-DXd in HER2+ breast cancer with or without brain metastases.

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Researchers call for early screening as young patients live longer.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Dr Danilov highlights advances and questions in the management of mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

Hope S. Rugo, MD, FASCO, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.